Globe Editorial
The Biotech industry is vital to Massachusetts and deserves robust protection of its intellectual property. But the long-awaited bills emerging from the House and Senate give too many years of exclusivity to the original makers of biotech drugs -- 12 instead of five for regular drugs -- and serve to drive up healthcare costs. A compromise is in order. (Full article: 495 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
